1st Neuralink patient can operate computer through thuoghts

Elon Musk

Rama Krishna Sangem

The first human patient who was implanted with a brain chip from Neuralink last month has fully recovered and is now able to control a computer mouse using their thoughts, Elon Musk said late on Monday. Musk is the founder of Neuralink.

According to a report by Reuters, in a Spaces event on social media platform X, Musk said, “Progress is good, and the patient seems to have made a full recovery, with neural effects that we are aware of. The patient is able to move a mouse around the screen by just thinking.”

He said that now Neuralink was trying to get as many mouse button clicks as possible from the patient. In January, Musk announced that his firm had successfully implanted a chip in its first human patient. It received approval for human trial recruitment in September.

Musk, however, did not provide additional details about the patient. When Neuralink announced in September that it would begin recruiting people, the company said it was searching for individuals with quadriplegia due to cervical spinal cord injury or amyotrophic lateral sclerosis, commonly known as ALS or Lou Gehrig’s Disease.


Chip planted in brain through robot surgery

The study uses a robot to surgically place a brain-computer interface implant in a region of the brain that controls the intention to move, Neuralink has said, adding that the initial goal is to enable people to control a computer cursor or keyboard using their thoughts.

Musk has grand ambitions for Neuralink, saying it would facilitate speedy surgical insertions of its chip devices to treat conditions like obesity, autism, depression, and schizophrenia. Neuralink, which was valued at about $5 billion last year, has faced repeated calls for scrutiny regarding its safety protocols.

Neuralink is a startup founded by Elon Musk in 2017. It’s trying to build a brain-computer interface that would help people with traumatic injuries operate phones and PCs using only their thoughts. To do that, they are working on implanting electrodes into people’s brains.


It will take a year to study

Typically, this type of study enrols 5-10 patients and lasts up to a year. The next step is a feasibility study and then a pivotal study, which is roughly analogous to a Phase III study for a drug. If all goes well, it will likely take between five years and a decade before commercialization.

Rama Krishna Sangem

Ramakrishna chief editor of excel India online magazine and website

Leave a Reply

Your email address will not be published. Required fields are marked *

Next Post

PM Modi dedicates IIT Hyderabad campus to nation

Tue Feb 20 , 2024
Rama Krishna Sangem In a historic moment, the Indian Institute of Technology Hyderabad (IITH) witnessed the dedication of its transformative Campus Development Project to the […]
IIT H dedicated to nation by PM

You May Like

Chief Editor

Rama Krishna Sangem

Excel India national news magazine is a media startup founded and piloted by Rama Krishna Sangem, a Hyderabad based senior journalist with over three decade experience in the field of media, mostly in print journalism. His rich experience in reporting for both Telugu and English newspapers and heading a TV news channel and some online outfits will be of immense use to this venture. Excel India English news magazine seeks to fill the gap of analytical understanding to our readers who today are confronted with myriad media platforms. Our online version not only offers regular updates and commentary on happenings around us, but also gives larger stories not limited by space constraints of a print magazine. Excel India is ably run by a team of senior journalists committed to values and quality standards in the profession. We urge you all to support and guide us in this endeavour. Reach us at excelindiaweb123@gmail.com